Table 2. In-hospital outcomes for 179 patients undergoing TA-TAVI at St. Paul’s hospital in Vancouver, Canada.
| Outcome | Overall (n=178) | Early cohort (n=89) | Late cohort (n=89) | P value |
|---|---|---|---|---|
| Hospital length of stay (days) | 12.2 (17.1) | 13.7 (22.1) | 10.6 (8.7) | 0.98 |
| Stroke | 6 (3.4) | 4 (4.5) | 2 (2.3) | 0.84 |
| Bleeding | 22 (12.6) | 18 (20.2) | 4 (4.7) | 0.004 |
| Vascular complication | 16 (9.1) | 13 (14.6) | 3 (3.5) | 0.02 |
| Blood transfusion | 78 (45.1) | 43 (48.3) | 35 (41.7) | 0.76 |
| Myocardial infarction | 5 (3.0) | 2 (2.2) | 3 (3.9) | 1.00 |
| Major adverse cardiovascular event | 29 (16.9) | 17 (19.1) | 12 (14.5) | 0.83 |
| GI complication | 4 (2.5) | 3 (3.4) | 1 (1.4) | 0.79 |
| Atrial fibrillation/Flutter | 23 (13.8) | 13 (14.9) | 9 (12.3) | 1.00 |
| Pneumonia | 17 (10.4) | 10 (11.2) | 7 (9.5) | 1.00 |
| Pulmonary embolism | 2 (1.2) | 2 (2.2) | 0 (0) | 0.39 |
| Prolonged ventilation | 10 (6.1) | 7 (7.9) | 3 (4.1) | 0.63 |
| Sepsis | 5 (3.1) | 3 (3.4) | 2 (2.7) | 1.59 |
| Wound infection | 7 (4.3) | 3 (3.4) | 4 (5.3) | 1.00 |
| Permanent pacemaker | 17 (9.9) | 7 (7.9) | 10 (12.0) | 0.72 |
| Acute renal failure | 23 (14.1) | 11 (12.4) | 12 (16.2) | 0.96 |
| Dialysis | 8 (5.0) | 5 (5.7) | 3 (4.1) | 1.00 |
| Cardiac arrest | 10 (6.2) | 5 (5.7) | 5 (6.8) | 1.00 |
| Mortality | 21 (12.1) | 15 (16.9) | 6 (7.1) | 0.09 |
Outcomes presented as mean (standard deviation) for continuous variables and number (percentage) for categorical variables. Early cohort - first 89 patients undergoing TA-TAVI; late cohort – next 89 patients undergoing TA-TAVI. P-value, comparing outcomes in early and late cohort, calculated using the Z-test for continuous variables and two-tailed chi square test for categorical variables